Levels of CCK immunoreactivity and dopamine in the nucleus accumbens after 6-hydroxydopamine lesions of the ventral tegmental area and the nucleus accumbens.
The effects of 6-hydroxydopamine (6-OHDA) injected into either the ventral tegmental area (VTA) or the nucleus accumbens on dopamine and its metabolite DOPAC and CCK-immunoreactivity in the nucleus accumbens were studied. Measurements were made 1, 3 and 6 weeks after the lesion in both the anterior and posterior part of the nucleus accumbens. 6-OHDA applied in the VTA reduced the level of DA and DOPAC, but did not affect the CCK content in the nucleus accumbens. 6-OHDA lesions in the anterior part of the nucleus accumbens produced depletion of DA and DOPAC from one week after the injection, and decreased the CCK content 6 weeks after the injection. The results suggest that in the nucleus accumbens DA and CCK are localized, at least for the major part, in different nerve terminals.
Igarashi
Y
Y
Rudolf Magnus Institute of Pharmacology, Medical Faculty, University of Utrecht, The Netherlands.
Wiegant
V M
VM
Van Ree
J M
JM
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002766:Cholecystokinin / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006892:Hydroxydopamines / Q000276:immunology / Q000494:pharmacology*; D008297:Male; D009714:Nucleus Accumbens / Q000378:metabolism* / Q000502:physiology; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D012686:Septal Nuclei / Q000378:metabolism*; D013681:Tegmentum Mesencephali / Q000378:metabolism* / Q000502:physiology
D006892:Hydroxydopamines; D015102:3,4-Dihydroxyphenylacetic Acid; D002766:Cholecystokinin; D004298:Dopamine